Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir for Refractory CMV Infection Following Allo-HSCT
NCT07511127Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of maribavir in cytomegalovirus infection (CMV), sponsored by Ruijin Hospital. Started Feb 2026; status: recruiting.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07511127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511127.